ODI — Odi Pharma AB (publ) Share Price
Last trade - 00:00- SEK41.06m
- SEK35.70m
- SEK22.29m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 92.27 | ||
| Price to Tang. Book | 92.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -702.95% | ||
| Return on Equity | -335.71% | ||
| Operating Margin | -14.54% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | 0.31 | 0.14 | 22.29 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Odi Pharma AB (publ) is a Swedish-based pharmaceutical company. The Company is a manufacturer and supplier of medical cannabis products. The business is run through subsidiaries and partners where sales are through wholesale distributors and pharmacies. The products are used for the treatment of, for example, multiple sclerosis, chronic pain and chemotherapy. The Company is located in Stockholm.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 21st, 2019
- Public Since
- January 23rd, 2020
- No. of Employees
- 1
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- AktieTorget Stock Exchange
- Shares in Issue
- 15,915,034
- Address
- Ostermalmstorg 1, STOCKHOLM, 11442
- Web
- https://www.odipharma.com/
- Phone
- Auditors
- PricewaterhouseCoopers AB
Similar to ODI
Cessatech A/S
AktieTorget Stock Exchange
Double Bond Pharmaceutical International AB (publ)
AktieTorget Stock Exchange
FAQ
As of Today at 22:24 UTC, shares in Odi Pharma AB (publ) are trading at SEK2.58. This share price information is delayed by 15 minutes.
Shares in Odi Pharma AB (publ) last closed at SEK2.58 and the price had moved by -54.65% over the past 365 days. In terms of relative price strength the Odi Pharma AB (publ) share price has underperformed the FTSE Global All Cap Index by -55.79% over the past year.
There is no consensus recommendation for this security.
Find out moreOdi Pharma AB (publ) does not currently pay a dividend.
Odi Pharma AB (publ) does not currently pay a dividend.
Odi Pharma AB (publ) does not currently pay a dividend.
To buy shares in Odi Pharma AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK2.58, shares in Odi Pharma AB (publ) had a market capitalisation of SEK41.06m.
Here are the trading details for Odi Pharma AB (publ):
- Country of listing: Sweden
- Exchange: AKT
- Ticker Symbol: ODI
Based on an overall assessment of its quality, value and momentum Odi Pharma AB (publ) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Odi Pharma AB (publ). Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -20.33%.
As of the last closing price of SEK2.58, shares in Odi Pharma AB (publ) were trading -34.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Odi Pharma AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK2.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Odi Pharma AB (publ)'s directors